ALRN vs. PDSB, UBX, CPIX, VCNX, CRMD, MGNX, NATR, RVNC, XOMA, and AMRN
Should you be buying Aileron Therapeutics stock or one of its competitors? The main competitors of Aileron Therapeutics include PDS Biotechnology (PDSB), Unity Biotechnology (UBX), Cumberland Pharmaceuticals (CPIX), Vaccinex (VCNX), CorMedix (CRMD), MacroGenics (MGNX), Nature's Sunshine Products (NATR), Revance Therapeutics (RVNC), XOMA (XOMA), and Amarin (AMRN). These companies are all part of the "pharmaceutical preparations" industry.
Aileron Therapeutics (NASDAQ:ALRN) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, community ranking, earnings, analyst recommendations, dividends and valuation.
Aileron Therapeutics presently has a consensus price target of $19.00, suggesting a potential upside of 497.48%. PDS Biotechnology has a consensus price target of $17.33, suggesting a potential upside of 514.66%. Given PDS Biotechnology's higher possible upside, analysts plainly believe PDS Biotechnology is more favorable than Aileron Therapeutics.
Aileron Therapeutics received 153 more outperform votes than PDS Biotechnology when rated by MarketBeat users. However, 67.42% of users gave PDS Biotechnology an outperform vote while only 66.98% of users gave Aileron Therapeutics an outperform vote.
90.9% of Aileron Therapeutics shares are owned by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are owned by institutional investors. 5.6% of Aileron Therapeutics shares are owned by insiders. Comparatively, 10.0% of PDS Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Aileron Therapeutics has a beta of 2.11, meaning that its share price is 111% more volatile than the S&P 500. Comparatively, PDS Biotechnology has a beta of 1.82, meaning that its share price is 82% more volatile than the S&P 500.
In the previous week, Aileron Therapeutics had 4 more articles in the media than PDS Biotechnology. MarketBeat recorded 4 mentions for Aileron Therapeutics and 0 mentions for PDS Biotechnology. PDS Biotechnology's average media sentiment score of 0.00 beat Aileron Therapeutics' score of -0.02 indicating that PDS Biotechnology is being referred to more favorably in the news media.
Aileron Therapeutics' return on equity of -95.55% beat PDS Biotechnology's return on equity.
PDS Biotechnology is trading at a lower price-to-earnings ratio than Aileron Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Aileron Therapeutics beats PDS Biotechnology on 10 of the 16 factors compared between the two stocks.
Get Aileron Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALRN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aileron Therapeutics Competitors List
Related Companies and Tools
